我要投票 茵花在女性洗液行业中的票数:433
· 外 推 电 报 ·
2025-08-22 08:40:48 星期五

【茵花是哪个国家的品牌?】

茵花是什么牌子?「茵花」是 重庆希尔安药业有限公司 旗下著名品牌。该品牌发源于重庆市,由创始人唐董在1994年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力茵花品牌出海!将品牌入驻外推网,定制茵花品牌推广信息,可以显著提高茵花产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

重庆希尔安药业有限公司,茵花洗液,女性洗液知名品牌,重庆市著名商标,集研发、生产、销售中药材种植/中药饮片加工为一体高新技术企业


希尔安药业起源于公元1698年的“伍舒芳草堂”,承袭“重庆中药总厂”之制药精髓,至今已有300多年的历史。公司始终秉持“德布天下,药济苍生”的企业理念,树百年商誉”为企业目标,如今已经发展成一家集研发、生产、销售于一体的综合性制药企业。

希尔安药业位于重庆市合川工业园区,总资产12.5亿元,占地面积330亩,Ⅰ期工程总建筑面积为76207m2,总投资达6亿元;颗粒剂、胶囊剂、片剂等15个剂型通过2010年版GMP认证,年产值将达到50亿元。新生产基地实现厂房标准化、生产过程自动化、环境保护科学化。

公司产品资源丰富,拥有生产批文166个,其中71个品种列入《国家基本医疗保险药品目录》;22个品种列入《国家基本药物目录》;12个中药保护品种,2个优质优价品种。

公司旗下两大商业机构:希尔安药品销售公司;希尔安康泽医药连锁有限公司;四大营销机构:处方药营销中心、OTC营销中心、普药营销中心、新医疗营销中心;实施“广覆盖、深耕作”营销战略,销售网络覆盖全国31个省、自治区、直辖市以及东南亚、欧洲、美洲等部分海外市场,形成从省会城市综合医院到区县以及乡镇卫生院、个体诊所、零售药房深度耕作的销售格局,致力于打造骨科、儿科、肿瘤科、皮肤科等多条具有竞争优势的产品线,实现每年销售额增长50%以上的目标。

公司下属两家研发机构:重庆思科药物研究所有限公司,专注于化药、中药及天然药物、大健康产品的开发;重庆科润生物医药研发有限公司,专注于生物制剂研发;拥有重庆市博士后科研工作站、重庆市企业技术中心、重庆市中药制剂工艺工程技术研究中心等多个市级技术创新平台。公司始终以“科技”为手段,坚持“仿创结合、药物与大健康产品研发并重”的方针,形成“筛选一批、研发一批、储备一批”的研发格局。

为了适应国家不断推进的医疗卫生体制改革以及新的经济形势,公司大力实施人才战略、品牌战略、创新战略;传承三百年伍舒芳中药文化精髓,构建以“德布天下,药济苍生”为核心的企业文化体系;打造市场准入和市场营销两大核心竞争力,实现颠覆式发展,力争在未来6~8年内,将希尔安打造成百亿级医药企业。


英文翻译:Chongqing hilan Pharmaceutical Co., Ltd., a famous brand of Yinhua lotion, women's lotion and Chongqing famous trademark, is a high-tech enterprise integrating R & D, production and sales of Chinese herbal medicine planting / processing of Chinese herbal pieces. Hilan pharmaceutical industry originated from wushufang thatched cottage in 1698 A.D., inherits the pharmaceutical essence of Chongqing general herbal medicine factory, and has a history of more than 300 years. The company always adheres to the enterprise concept of "debuxia, medicine for the people" and the enterprise goal of "building a hundred years' goodwill". Now it has developed into a comprehensive pharmaceutical enterprise integrating research and development, production and sales. Hilan pharmaceutical is located in Hechuan Industrial Park, Chongqing, with a total asset of 1.25 billion yuan, covering an area of 330 mu. The total construction area of phase I project is 76207m2, with a total investment of 600 million yuan. 15 dosage forms such as granules, capsules and tablets have passed GMP certification in 2010, with an annual output value of 5 billion yuan. The new production base realizes factory standardization, production process automation and environmental protection scientization. The company has rich product resources, with 166 production approvals, 71 of which are listed in the national basic medical insurance drug catalog; 22 of which are listed in the national basic drug catalog; 12 of which are protected by traditional Chinese medicine, and 2 of which are of high quality and high price. The company's two major commercial organizations: hilan pharmaceutical sales company; hilan Kangze pharmaceutical chain Co., Ltd.; four major marketing organizations: prescription drug marketing center, OTC marketing center, general drug marketing center, new medical marketing center; the implementation of the "wide coverage, deep cultivation" marketing strategy, the sales network covers 31 provinces, autonomous regions, municipalities directly under the central government, as well as Southeast Asia, Europe, the United States Some overseas markets, such as Zhouzhou, have formed a sales pattern of deep cultivation from provincial capital city general hospitals to district and county health centers, individual clinics and retail pharmacies. They are committed to building multiple product lines with competitive advantages, such as orthopedics, pediatrics, oncology and dermatology, to achieve the goal of increasing sales by more than 50% every year. Two R & D institutions under the company: Chongqing Cisco Pharmaceutical Research Institute Co., Ltd., which focuses on the development of chemical medicine, traditional Chinese medicine, natural medicine and large health products; Chongqing Kerun biomedical research and Development Co., Ltd., which focuses on the research and development of biological agents; Chongqing postdoctoral research station, Chongqing enterprise technology center, Chongqing Traditional Chinese medicine preparation process engineering technology research center, etc Municipal technology innovation platforms. The company always takes "science and technology" as a means, adheres to the policy of "combination of imitation and innovation, equal emphasis on research and development of drugs and large health products", and forms a research and development pattern of "selecting a batch, researching and developing a batch, and reserving a batch". In order to adapt to the constantly advancing medical and health system reform and the new economic situation, the company vigorously implements the talent strategy, brand strategy and innovation strategy; inherits the essence of Wu Shufang's traditional Chinese medicine culture for three hundred years, constructs the enterprise culture system with the core of "debriefing the world, medicine saving the people"; creates the two core competitiveness of market access and marketing, and realizes the subversive development, Strive to build hilan into a 10 billion level pharmaceutical enterprise in the next 6-8 years.

本文链接: https://www.waitui.com/brand/7094bf05f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

“创新+国际化”步伐加快,多家创新药企“中考成绩”亮眼

记者梳理发现,截至目前,百济神州、翰森制药等多家创新药企披露上半年业绩情况,创新药收入情况、研发管线进展、出海规划等成为市场关注焦点。业内人士表示,当前我国创新药相关企业已经实现从量变到质变的转化,逐渐从“跟跑者”到“引领者”。创新药板块景气度有望持续,“创新+国际化”步伐逐渐加快,成为医药板块的核心方向。(中证报)

41分钟前

商业化带动需求提升,eVTOL动力电池路径渐明

随着eVTOL(电动垂直起降飞行器)订单密集落地,其商业化进程不断加速。与此同时,GWh级别的电池需求也逐渐显现。专家表示,面对航空级电池更为严格的要求,固态电池因兼具高能量密度与高安全性的特点,应用潜力较大,或将成为eVTOL厂商的核心选择。不过,固态电池在技术、供应链、成本等方面仍存在亟待突破的难题,其商业化之路依然漫长。在此背景下,混动路线成为部分厂商关注的焦点。业内预计,在未来相当长一段时间,混动路线会在eVTOL领域占有一席之地。(上证报)

41分钟前

马斯克称SpaceX明年收入将超过NASA预算

马斯克周四在X平台上发帖称:“SpaceX今年将从NASA获得的收入大约是10亿美元,约占150亿美元总收入的7%。”一位用户评论称:“很快,SpaceX的收入可能就会超过NASA的全部预算。”马斯克回应称:“明年。”根据美国白宫今年5月份公布的2026财年联邦支出预算提案,美国国家航空航天局(NASA)2026财年分配预算为188亿美元,较2025财年实际获得的249亿美元下降了近25%。(新浪财经)

41分钟前

稀土价格快速走高,稀土板块迎来业绩反转

稀土主要品种价格快速走高,8月以来平均上涨超过10万元/吨。与此同时,永磁体价格也快速走高,钕铁硼N35最新报价144.5元/千克,月内涨幅10.7%,年内涨幅51.3%。2024年,稀土价格大幅走低,A股稀土板块业绩暴跌,在业绩低基数和稀土价格走高的双重影响下,今年稀土板块迎来业绩反转。据数据宝统计,截至8月21日,已有14家稀土永磁个股发布上半年业绩数据(含预告、快报和年报),多数公司业绩预增或扭亏。龙头股北方稀土净利润更是同比暴增超18倍。(证券时报)

41分钟前

特斯拉未及时提交事故报告,美监管部门对其发起审查

美国国家公路交通安全管理局(NHTSA)下属缺陷调查办公室当地时间8月19日称,特拉斯未按照规定及时提交事故报告,NHTSA因此将启动审查,评估潜在报告延迟的原因、延迟的范围,以及特斯拉为解决这些问题所采取的缓解措施。作为此次审查的一部分,NHTSA还将评估是否仍有先前事故的报告未提交,以及已提交的报告是否包含所有必要且可用的数据。(界面)

41分钟前

本页详细列出关于茵花的品牌信息,含品牌所属公司介绍,茵花所处行业的品牌地位及优势。
咨询